One-Shot gene therapy aims to end monthly eye injections for wet AMD
NCT ID NCT07178249
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This early-stage trial tests EXG202, a gene therapy given as a single injection into the eye for people with wet age-related macular degeneration (AMD). The goal is to see if it is safe and can produce a protein that blocks abnormal blood vessel growth long-term, potentially reducing the need for frequent anti-VEGF injections. About 60 participants aged 50 and older with active wet AMD will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- EXG202 (gene therapy injection)
- What this could lead to
- If successful, this one-time gene therapy could reduce or eliminate the need for frequent eye injections for wet AMD, helping maintain vision with less hassle.
- What could go wrong
- This is an early phase I/II trial with only 60 participants, so safety and effectiveness are not yet proven. Gene therapy carries risks like inflammation or immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2025
An estimate. Start dates often move.
- Expected to finish
-
Dec 2032
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female, aged ≥50 years old; 2. The study eye must be diagnosed of wAMD and current active lesions; 3. Subjects have clear refractive media and sufficient pupil dilation at the time of screening to obtain high-quality retinal images for confirmation of diagnosis; 4. Subjects (including male subjects) have no pregnancy plans during the screening period and the entire trial period and voluntarily take effective contraceptive measures and have no sperm or egg donation plans; 5. Subjects are Voluntarily participate in this clinical trial, understand the research procedures and sign the informed consent form before screening; subjects have good compliance and are willing to abide by the research procedures. Exclusion Criteria: 1. The study eye has any eye disease other than wAMD that may affect central vision and/or macular detection ; 2. The study eye has a history of retinal detachment or retinal detachment during the screening period; 3. The study eye has MNV caused by reasons other than wAMD (such as diabetic retinopathy, pathological myopia, retinal vein occlusion, angioid streak disease, ocular histoplasmosis, trauma, etc.), and a history of macular pathology unrelated to wAMD; 4. Any intraocular surgery is planned for the study eye during the study period; 5. The study eye currently has retinal angiomatous proliferation (RAP), central serous chorioretinopathy or symptomatic vitreomacular traction syndrome; 6. Presence of glaucoma or optic neuropathy that involves or compromises the central visual field of the study eye or presence of uncontrolled high intraocular pressure in the study eye; 7. The fellow eye meets the definition of legal blindness; 8. Hormone-induced increased intraocular pressure in any eye; 9. Active infection in any eye this trial (such as those who cannot understand and comply with the trial requirements or are deemed unsuitable for safety reasons).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Wet age related macular degeneration are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New eye drug goes Head-to-Head with standard treatment for wet AMD
- New eye drug goes Head-to-Head with standard care for wet AMD
- Eye drops could replace injections for wet AMD
- Could eye drops replace injections for a leading cause of blindness?
- Eye injection burden varies by disease, study finds
- New hope for wet AMD patients: a simple pill may drain stubborn eye fluid